Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Revlimid Ordered to Add Label Warning for Hep B Virus Reactivation
January 11, 2017
- Chuikyo to Kick Off Debates to Elaborate Pricing Revamp; 2 Industry Hearing Sessions Planned
January 11, 2017
- “Drug Value Assessments Will Be Critical”; High-Priced Innovative Drugs to Be a Topic at OECD Meeting: Health Minister
January 10, 2017
- MHLW to Regularly Compile Optimal Drug Use Guidelines from FY2017: Pharma Bureau Chief
January 6, 2017
- From Regulatory Agency to Industry-Fostering Agency: Health Minister
January 5, 2017
- MHLW to Draw Up Genomic Medicine Project by Summer: Minister
January 5, 2017
- Policymakers Rolling Up Their Sleeves to Embody Drug Pricing Overhaul
January 1, 2017
- AMED Plans to Introduce Medical-Economic Viewpoints for Its R&D Support
December 28, 2016
- PMDA Announces 5 Themes for Trial of MID-NET Including Codeine, Denosumab
December 28, 2016
- HPV-Unvaccinated Teens Show Symptoms Similar to Post-Vaccine Reactions: Study
December 27, 2016
- MHLW Health Service Bureau’s FY2017 Budget at 369.2 Billion Yen
December 27, 2016
- MHLW Gives Orphan Status to Avelumab, 2 Other Compounds
December 26, 2016
- MHLW Allots 300 Million Yen for Health Minister-Pushed Startup Consultations
December 26, 2016
- MHLW Pharmaceutical Safety Bureau Earmarks 230 Mil. Yen for New Guidelines Initiative
December 26, 2016
- MHLW’s FY2017 Budget Up 1.2% at 30.7 Trillion Yen
December 26, 2016
- MHLW to Set Up MID-NET Usage Fees to Induce Drug Makers to Use It for PMS: Official
December 26, 2016
- AMED’s FY2017 Budget Earmarks 126.5 Billion Yen for Medical R&D
December 26, 2016
- Govt’s FY2017 Budget Includes 32 Trillion Yen for Social Security Spending
December 26, 2016
- PM Abe’s Panel to Keep Vigilant Eyes on Drug Prices, Reimbursement Fees
December 22, 2016
- Chuikyo to Discuss Annual Price Revision Plan in Concert with CEFP: Official
December 22, 2016
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…